Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome

Trial Profile

Apixaban for the Secondary Prevention of Thromboembolism: A Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Apixaban (Primary) ; Warfarin
  • Indications Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASTRO-APS
  • Most Recent Events

    • 29 Dec 2016 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 29 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
    • 05 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top